Basel-based precision medicine company Indivi has successfully closed a CHF 15 million investment round led by Ava Investors, marking a significant milestone in the company's mission to transform neuroscience drug development through advanced biomarker discovery. The funding will accelerate validation and deployment of Indivi's precision medicine tools specifically targeting Alzheimer's disease, addressing one of medicine's most challenging therapeutic areas.
The investment enables Indivi to launch a pivotal proof-of-concept trial in 2026 focused on identifying functional and electrophysiological biomarkers that demonstrate superior pharmacodynamic responses in Alzheimer's disease modification through β-amyloid-depleting therapies. The anticipated results could establish novel, more sensitive biomarkers that improve the ability to detect early treatment efficacy signals in Alzheimer's disease clinical trials.
Addressing Critical Challenges in Neuroscience Drug Development
"The field of neurodegeneration remains one of the toughest challenges in medicine," said Shibeshih Belachew, Chief Medical Officer of Indivi. "We are thrilled to bolster our efforts to augment the success rate of promising assets to reach the Proof-of-Concept stage, where conventional endpoints lack the sensitivity needed to detect early treatment effects."
The investment comes at a critical juncture for the neuroscience sector, which continues to face significant challenges in developing effective therapies for neurodegenerative diseases. Indivi's approach aims to improve the probability of clinical success by integrating accessible deep phenotyping technologies into drug development processes.
Proprietary Deep Phenotyping Platform
Indivi's platform focuses on capturing early treatment benefits in complex neurological diseases using proprietary software for deep phenotyping. The company's integrated approach combines functional and biological measurements, including electrophysiology and sensor-derived assessments, to deliver earlier and more definitive Proof-of-Biology and Proof-of-Concept signals in neuroscience research.
"Our mission is to make measurable what is not so, by capturing early treatment benefits on complex neurological disease traits through accessible deep phenotyping software technologies," said Guilhem Dupont, CEO of Indivi.
The ISO 13485 and ISO 27001-certified company develops functional biomarkers for multiple neurological and neuromuscular conditions, including multiple sclerosis, Parkinson's disease, Alzheimer's disease and related dementias, as well as muscular dystrophies. Through its partnership with Clouds of Care, Indivi has established a unified R&D framework for multimodal deep phenotyping.
Strategic Value Proposition
By enhancing the signal-to-noise ratio of early-stage clinical endpoints, Indivi's integrated approach de-risks early clinical development, increases the likelihood of regulatory success, and improves the risk-adjusted net present value for biopharmaceutical partners seeking to advance therapies for neurodegenerative diseases. The technology-integrated platform aims to accelerate time-to-market while enhancing the probability of technical and regulatory success for partner companies.
